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Abstract
Background: Allergic rhinitis and asthma are conditions of airway inflammation that often coexist.
Discussion: In susceptible individuals, exposure of the nose and lungs to allergen elicits early phase
and late phase responses. Contact with antigen by mast cells results in their degranulation, the
release of selected mediators, and the subsequent recruitment of other inflammatory cell
phenotypes. Additional proinflammatory mediators are released, including histamine,
prostaglandins, cysteinyl leukotrienes, proteases, and a variety of cytokines, chemokines, and
growth factors. Nasal biopsies in allergic rhinitis demonstrate accumulations of mast cells,
eosinophils, and basophils in the epithelium and accumulations of eosinophils in the deeper
subepithelium (that is, lamina propria). Examination of bronchial tissue, even in mild asthma, shows
lymphocytic inflammation enriched by eosinophils. In severe asthma, the predominant pattern of
inflammation changes, with increases in the numbers of neutrophils and, in many, an extension of
the changes to involve smaller airways (that is, bronchioli). Structural alterations (that is,
remodeling) of bronchi in mild asthma include epithelial fragility and thickening of its reticular
basement membrane. With increasing severity of asthma there may be increases in airway smooth
muscle mass, vascularity, interstitial collagen, and mucus-secreting glands. Remodeling in the nose
is less extensive than that of the lower airways, but the epithelial reticular basement membrane
may be slightly but significantly thickened.
Conclusion: Inflammation is a key feature of both allergic rhinitis and asthma. There are therefore
potential benefits for application of anti-inflammatory strategies that target both these anatomic
sites.
Introduction
Asthma is a chronic, inflammatory condition of the lower
airways characterized by largely reversible airflow obstruc-
tion, airway hyperresponsiveness, and episodic respira-
tory symptoms, including wheezing, productive cough,
and the sensations of breathlessness and chest tightness
[1]. Allergic rhinitis (AR), also often associated with con-
junctival symptoms, is a disorder of the upper airways
(namely, above the larynx) resulting from IgE-mediated
inflammation of the nose upon contact of the nasal
mucosa with allergens: symptoms include rhinorrhea,
nasal itching, sneezing, and nasal obstruction [2]. The pat-
terns of inflammation, when stable or in response to
experimental allergen challenge, are similar in the upper
and lower airways. Moreover, both asthma and AR may be
associated with evidence of systemic inflammation.
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Often, as discussed in the prior article in this supplement
[3], asthma and AR are comorbid conditions [2,4], with
AR being a major risk factor for the occurrence of asthma
[5].
In the present article, we summarize the patterns of
inflammation of the upper and lower airways; we empha-
size the need to consider treating the inflammation that is
common to both. We introduce briefly techniques cur-
rently used to describe characteristic cells and mediators
of inflammation common to both asthma and AR. Of
course, patients with asthma, as well as AR, can demon-
strate a spectrum of symptoms clinically and, likewise, of
inflammatory changes. As more data emerge it is likely
that distinct phenotypes of both AR and asthma will
become accepted. Despite this, there are some obvious
similarities in the patterns of inflammation yet differences
in the extent of remodeling.
Evaluating the airways for inflammation
With the exception of the anterior nares and a good pro-
portion of the nasopharynx and larynx (which are kerati-
nized and stratified squamous, respectively), the
microscopic anatomy of normal nasal and bronchial
mucosa is similar: a pseudostratified epithelium resting
on a reticular basement membrane with underlying sub-
epithelium (that is, lamina propria). The epithelium is
composed of columnar ciliated cells interspersed by gob-
let cells [6], and beneath (in the subepithelium and sub-
mucosa) there are blood vessels, fibroblasts, nerves,
mucous glands, and immune cells. The differences
between nose and bronchi include the greater abundance
of subepithelial capillaries and the venous cavernous
sinusoids present in the nose and the presence of encir-
cling airway smooth muscle in the lower airways, absent
from the nose [6,7].
There are several techniques for evaluating inflammation
in lower or upper airways in both clinical and research set-
tings. The lower airways can be investigated by rigid or
flexible fiberoptic rhinoscopy and bronchoscopy [8-10].
Bronchoscopy is used to collect endobronchial biopsies or
brushings as well as bronchoalveolar lavage. Nasal sam-
pling includes biopsy, with and without the aid of rhinos-
copy, and cytology can be assessed in lavage or nasal
swabs [11]. Expelled secretions for analysis include
induced sputum from the lower airways and nasal mucus
from the upper airways. Biopsy permits histopathological,
immunohistological, and molecular examination of res-
piratory mucosa. Cytological examination of secretions
can add useful information to that obtained by direct
examination of the mucosa: these complementary tech-
niques sample two distinct compartments [12]. Measure-
ment of biological markers in airway and nasal secretions
can also be made before and after endobronchial provo-
cation with allergen or pharmacological or physical agents
in order to study the dynamics of the inflammatory
responses to such challenges [9,13].
Bronchoscopy has its limitations. It samples only a small
portion of the entire lung and in its airways, only the
superficial portion of the bronchial wall is sampled. While
possible, examination of the smaller (2–3 mm) airways is
difficult in practice and there are greater safety and ethical
issues. Moreover, bronchoscopy may not be practical in
severely compromised adults or pediatric patients [9]
although, in the latter, recent studies have been published
that aim to elucidate the patterns of inflammation and
remodeling that occur as asthma becomes first recognized
clinically [14-16]. The usefulness of nasal and bronchial
cytology is also limited by considerable intra-individual
variability as well as variability according to collection
technique [11,13,17]. In disorders of airflow obstruction,
there is now a greater appreciation of the need to also
understand the distinct contributions to variability in the
lower airways [18]. Additionally, the fractional concentra-
tion of exhaled nitric oxide may be a useful measure to
assess airway inflammation in diagnostic work or to mon-
itor the effects of anti-inflammatory therapy, even in chil-
dren [19-23]. Finally, peripheral blood eosinophilia is
common in AR and asthma, and it reflects the presence of
systemic inflammation [24].
Changes in the upper airways in allergic rhinitis
The inflammatory cascade in the nose begins with aller-
gen deposition on the nasal mucosa and consists of early
phase responses and, in many cases, late phase responses
in susceptible individuals. Upon activation by antigen via
cross-linking of IgE receptors, sensitized mast cells imme-
diately degranulate, releasing a variety of inflammatory
mediators, including histamine, prostaglandin D2, cystei-
nyl leukotrienes, and neutral proteases [2,25]. These
mediators cause sensory neural stimulation and plasma
exudation from blood vessels, which the patient experi-
ences as itching, sneezing, nasal discharge, and conges-
tion. Other localized cells involved in the allergic
response include Langerhans' cells, which are dendritic
cells that present antigen to the mast cells, and T helper
type 2 lymphocytes, which indirectly regulate the produc-
tion of IgE. Recruitment of inflammatory cells, including
eosinophils, basophils, and T cells, results in further
release of histamine and leukotrienes, as well as other
compounds including proinflammatory cytokines and
chemokines, sustaining the allergic response and promot-
ing the late phase response that may occur 6–9 hours after
allergen exposure [26,27].
Nasal biopsies of patients with active AR show accumula-
tions of mast cells, eosinophils, and basophils in the epi-
thelium and an accumulation of eosinophils in the deeperBMC Pulmonary Medicine 2006, 6(Suppl 1):S5
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lamina propria [27]. In time, the reticular basement mem-
brane may appear slightly but significantly thickened, but
not to the extent seen in the lower airways in asthma (see
discussion of remodeling below). Remodeling in the nose
appears to be less extensive than that in the lower airways
[6,24]. While this requires further study, two reasons pos-
tulated for the differences in remodeling between upper
and lower airways include the secretory activity of smooth
muscle cells present in bronchi but not in the nose, and
the differences in embryologic origins of the bronchi and
the nose [6].
Changes in the lower airways in asthma: 
inflammation and remodeling
Both inflammation and structural changes (referred to as
remodeling) occur in the tracheobronchial tree of patients
with asthma. It has been generally considered that chronic
eosinophilic inflammation is a prerequisite for the devel-
opment of remodeling, and there is some animal experi-
mental evidence to support this [28]. Investigations in
humans to discover whether chronic inflammation leads
to remodeling or whether remodeling begins first are in
their infancy [14-16,29]. Such studies are required so that
we may determine if and when there may be a 'window of
opportunity' for prevention of the structural and inflam-
matory changes associated with the asthma phenotype.
Moreover, it may become possible to predict which pre-
school 'wheezers' will go on to develop asthma.
Airway inflammation can be present even in patients with
normal lung function but with symptoms indicative of
asthma [30]; hence, measurements of the forced expira-
tory volume in 1 second do not reflect well or predict air-
way inflammation. Conversely, symptomatic infants with
reversible airflow obstruction (that is, asthma) may not
demonstrate evidence of either bronchial tissue eosi-
nophilia or remodeling [15]. Considering that these path-
ological changes are present and maximal in severely
asthmatic school children of median age 10 years [14], the
changes must begin earlier. There are now new data indi-
cating that the changes begin between the ages of 1 and 3
years and that there is a positive relationship between tis-
sue eosinophilia and reticular basement membrane thick-
ening at this time [29].
Chronic inflammation plus remodeling contribute to air-
way wall thickening, which encroaches upon the airway
lumen and increases resistance to airflow (Figure 1). Air-
way secretions also contribute to the pathology of asthma,
and especially to the consequences of acute, severe, life-
threatening exacerbations. In those rare cases when a fatal
asthma attack has occurred after a short duration of
asthma, airway wall thickening may not be present – and
in these cases patient demise is assumed to be secondary
to asphyxiation from tenacious, sticky mucus admixed
with an inflammatory eosinophilic exudate in the airways
(Figure 2) [31].
Inflammation in asthma
Lymphocytic inflammation enriched by eosinophils is
characteristic of the bronchi in mild asthma in both adults
and school children, and also of the bronchi and luminal
secretions in fatal asthma (Figures 3 and 4). In severe dis-
ease the predominant pattern changes because, in addi-
tion to eosinophils, neutrophils increase, and the
inflammation may spread to include the small airways
(that is, airways 2 mm or smaller in diameter) [32].
In allergic asthma, inhaled allergens that penetrate the
mucociliary lining layer enter the airway epithelium either
via the tight junctions that surround the apical zone of
bronchial epithelial cells or by direct uptake by the cells
per se. As occurs in the nose, the sequence of reactions in
the lungs may include both early phase and late phase
responses. There is presentation of antigen to mast cells,
cross-linking of cell surface IgE, degranulation of mast
cells, release of mediators such as histamine and leukot-
rienes that markedly increase vascular permeability, fol-
lowed by recruitment of more inflammatory cells, and
further release of proinflammatory mediators.
In asthma, the predominant orchestrator of the chronic
inflammation is the CD4 or T-helper lymphocyte, produc-
ing key regulatory cytokines such as IL-5 and IL-4 [33].
Eosinophils (originating in the bone marrow) are released
into the circulation, resulting in blood eosinophilia,
partly in response to IL-5. The eosinophils are selectively
retained at bronchial microvascular surfaces by tumor
necrosis factor alpha-induced and IL-4-induced upregula-
tion of adhesive molecules. Once retained they are
recruited into the mucosa (Figure 5) and migrate to the
surface epithelium where they cross it, in response to eosi-
nophil chemoattractants released by structural and
immune elements. The then-activated eosinophils release
highly toxic granules that damage the surface epithelial
cells, loosening their attachments and resulting in their
loss into the airway lumen, where they admix with both
eosinophils and excess mucin.
Eosinophil chemoattractants include, for example,
eotaxin, macrophage/monocyte chemotactic protein 4,
RANTES, and cysteinyl leukotrienes [34]; these chemoat-
tractants act on distinct cell surface receptors (CC chem-
okine receptor 3 and cysteinyl leukotriene type 1 (cysLT1)
receptor) present on the eosinophil, but not exclusively
so. In support of this, challenge with leukotriene E4 results
in greatly increased numbers of eosinophils in the bron-
chial wall [34]. Moreover, a recent study in asthma has
used the molecular techniques of in situ hybridization and
immunohistochemistry to localize cells that express eitherBMC Pulmonary Medicine 2006, 6(Suppl 1):S5
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the mRNA or the protein for the cysLT1 receptor, respec-
tively [35]. In addition to the eosinophil, the receptor
appears to be present on a variety of bronchial inflamma-
tory cells (Figure 6), including neutrophils, mast cells,
macrophages, B lymphocytes, and plasma cells. The study
also demonstrated that the numbers of inflammatory cells
expressing the cysLT1 receptor are increased – in compari-
son with normal healthy nonsmokers – in nonsmoking
patients with mild, stable asthma and that there is a fur-
ther increase among patients experiencing a severe exacer-
bation of asthma leading to hospitalization (Figure 7)
[35].
Remodeling in asthma
Remodeling in asthma has been defined as a change in
structure that is inappropriate to the maintenance of nor-
mal airway function [33]. Remodeling is evident even in
newly diagnosed or mild asthma and is characterized by
epithelial fragility and reticular basement membrane
thickening. With increasing severity of asthma, there are
increases of airway smooth muscle mass, vascularity,
numbers of fibroblasts, and interstitial collagen, as well as
mucous gland hypertrophy [33]. These changes appear to
be greatest in the larger, more proximal airways.
Thickening of the reticular basement membrane occurs
early in asthma (Figure 8), even before diagnosis, and is
detected in children with mild asthma [16]. It most prob-
ably reflects the response to ongoing epithelial injury and
regeneration, in which eosinophils play a role [36]. In
school children between the ages of 6 and 16 with severe
asthma the membrane is already maximally thickened,
but there is no significant association between its thick-
ness and age or symptom duration [14]. These changes
appear in preschool wheezy children by the age of 29
months [29].
Airway smooth muscle surrounds the airways as two
opposing helices; namely, in a geodesic pattern. As the
muscle shortens, therefore, it not only constricts but tends
Thickening of the bronchial wall in asthma Figure 1
Thickening of the bronchial wall in asthma. Schematic illustrating the thickening of the bronchial wall in asthmatic condi-
tions (right) as compared with normal conditions (left). Reprinted with permission from Jeffery [65].BMC Pulmonary Medicine 2006, 6(Suppl 1):S5
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to shorten the airway against an elastic load. Leukotrienes
are very powerful constrictors of airway smooth muscle,
being 1000-fold or 2000-fold more active than histamine.
There are at least three possible mechanisms of smooth
muscle mass enlargement in asthma: myocyte hypertro-
phy, myocyte hyperplasia due to cell division and prolif-
eration, or myocyte de-differentiation and migration
across the mucosa in the form of myofibroblasts or fibro-
myocytes. It is speculated that these may then re-differen-
tiate to form new blocks of smooth muscle that come to
lie just below (external to) the epithelium [33].
Greater numbers of mast cells have recently been found
located within the bronchial smooth muscle of patients
with asthma than in those with eosinophilic bronchitis –
the latter is also a condition of airway eosinophilia and
remodeling but without the functional abnormalities
characteristic of asthma. The difference in smooth muscle
mast cell number that discriminates between these condi-
tions has led to the hypothesis that the infiltration of air-
way smooth muscle by mast cells is responsible for the
disordered airway function characteristic of asthma, and
thus that asthma is the result of a mast cell myositis [37].
These and other data highlight the importance of the
localization of inflammatory cells to distinct tissue com-
partments rather than their overall number per se. No
doubt there will be many more studies to test this hypoth-
esis.
Interactions between asthma and allergic 
rhinitis
Allergic asthma and AR are often considered clinical man-
ifestations of the same condition, the chronic allergic res-
piratory syndrome [38,39]. The many epidemiological
associations between the two conditions are reviewed in
the prior article in this supplement [3]. Moreover, as dis-
cussed previously [3], bronchial hyperresponsiveness is
common in people with AR, even if they have no symp-
toms of asthma, and bronchial inflammation can result
from nasal allergen challenge in patients with AR in the
Plugging of the airways in fatal asthma Figure 2
Plugging of the airways in fatal asthma. Gross view of a sliced lung specimen to show plugging of the airways in fatal 
asthma. Reprinted with permission from Jeffery [65].BMC Pulmonary Medicine 2006, 6(Suppl 1):S5
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absence of obvious asthma [40]. Conversely, patients with
asthma can have eosinophilic infiltration of their nasal
mucosa without reporting the symptoms of rhinitis
[38,39]. Segmental bronchial provocation in patients
with AR but not asthma has been shown to induce nasal
inflammation [41,42]. Not all patients with asthma have
rhinitis, however, and not all patients with rhinitis have
asthma. Genetic differences contribute to this discrep-
ancy; for example, certain haplotypes of the newly identi-
fied GPR154 gene on chromosome 7 predispose
individuals to IgE-mediated rhinitis but not to asthma
[43].
Possible mechanisms for the influence of AR on lower air-
ways include disturbance of the beneficial role of nasal
mucosa in conditioning the air entering the respiratory
tree; neural interaction between upper and lower airways;
irritant effects of nasal secretions directly entering the
lower airways; and systemic propagation of nasal inflam-
mation to the bronchial mucosa (or vice versa) via effects
of mediators and inflammatory cells on bone marrow –
'systemic cross-talk' [38,40,44].
Effects of anti-inflammatory treatment in 
allergic rhinitis and asthma – proof of concept
Nasal corticosteroids, antihistamines, and the leukotriene
receptor antagonist (LTRA) montelukast have each been
shown to have anti-inflammatory effects on different
aspects of inflammation in AR, and these effects have been
recently reviewed [45].
In patients with asthma, inhalation of corticosteroids
(ICS) produces reductions in bronchial inflammation by
days or weeks, whereas reductions in reticular basement
membrane thickening are achieved over longer periods,
after about 1 year [46]. Treatment with montelukast
reduces peripheral eosinophil counts and eosinophils in
induced sputum [47]. Short-term treatment (that is, 4
weeks) with another LTRA, pranlukast, reduces bronchial
inflammation in endobronchial biopsies [48]. Moreover,
Plug of eosinophil-rich inflammatory exudate and mucus in the airway of a patient with asthma Figure 3
Plug of eosinophil-rich inflammatory exudate and mucus in the airway of a patient with asthma. Concentric 
lamellae of eosinophils appear blue (alkaline phosphatase antialkaline phosphatase). Reprinted with permission from Jeffery 
[65].BMC Pulmonary Medicine 2006, 6(Suppl 1):S5
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there is in vitro evidence from isolates and cultures of
human airway smooth muscle that leukotrienes enhance
myocyte proliferation and migration, processes that can
be attenuated by LTRAs [49-51].
The clinical benefits of early treatment with anti-inflam-
matory therapy for asthma were shown in studies in the
early 1990s [52,53]. In 1994, the Finnish asthma program
was established to reduce morbidity of asthma in Finland
with a focus on treating inflammation, as implemented by
a network of asthma-responsible doctors, nurses, and
pharmacists. While this program has not halted the
increase of asthma in Finland, disability pensions and the
number of hospital bed-days for asthma and deaths from
asthma have considerably decreased over 10 years [54].
This outcome can be attributed mainly to more effective
and early use of anti-inflammatory medication.
Several recent studies have shown that there is still room
for improvement in anti-inflammatory treatment of
patients with asthma. There are several arguments that
favor the combined use of ICS and an LTRA in asthma.
First, cysteinyl leukotriene levels in induced sputum
remain increased in patients with asthma receiving ICS,
suggesting that corticosteroids do not suppress leukot-
riene production [55]. Also, the addition of the LTRA
montelukast improves clinical endpoints, with a 56%
increase in asthma-free days, for patients with persistent
disease who were receiving ICS [56]. Finally, in the
IMPACT study, montelukast added to fluticasone gave the
same level of protection against asthma exacerbation as
did the addition of a long-acting β2-agonist [57]. Among
the Finnish patients in this study, the mean sputum eosi-
nophil count fell significantly at week 24 in those receiv-
ing montelukast but not in those patients receiving
salmeterol [57].
Eosinophils in the airway wall in fatal asthma Figure 4
Eosinophils in the airway wall in fatal asthma. Fatal asthma with eosinophils (blue) in the airway wall showing the origin 
of the eosinophils that migrate across the mucosa, enter the lumen, and contribute to the inflammatory exudate shown in the 
previous figure. Reprinted with permission from Jeffery [65].BMC Pulmonary Medicine 2006, 6(Suppl 1):S5
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Eosinophil emerging from a bronchial vessel to enter the bronchial mucosa Figure 5
Eosinophil emerging from a bronchial vessel to enter the bronchial mucosa. Eosinophil emerging from a bronchial 
vessel to enter bronchial mucosa, as seen by transmission electron microscopy. Reprinted with permission from Jeffery [65].
Colocalization of the cysteinyl leukotriene type 1 receptor with eosinophils in asthma exacerbation Figure 6
Colocalization of the cysteinyl leukotriene type 1 receptor with eosinophils in asthma exacerbation. Double 
immunofluorescence staining for identification of colocalization of the cysteinyl leukotriene type1 (cysLT1) receptor with eosi-
nophils in a bronchial biopsy from a patient with asthma with severe exacerbation. (a) cysLT1-receptor protein immunopositiv-
ity is illustrated with Texas red fluorescence. (b) Eosinophils stained with anti-human EG2 coupled to fluorescein isothiocyanate 
conjugate. (c) EG2
+ eosinophils (internal scale bar = 10 μm). Nuclei are counterstained blue with 4',6-diamidino-2-phenylindole. 
EG2 is a monoclonal antibody to the cleaved (activated) form of eosinophil cationic protein. Reprinted with permission from 
Zhu and colleagues [35].BMC Pulmonary Medicine 2006, 6(Suppl 1):S5
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For patients with comorbid AR and asthma, effective man-
agement of their rhinitis may also improve the coexisting
asthma [2]. As discussed in the preceding paper of the
present supplement [3], observational studies have shown
the benefits of treating rhinitis in terms of reduced risk of
hospitalizations or emergency department visits for
asthma [58]. Montelukast improves lung function in
patients who have rhinitis [59,60], and daily rhinitis
symptoms improve when montelukast is given to patients
with hay fever and asthma – as do patients' and physi-
cians' global evaluations of asthma symptoms [61].
Finally, the World Allergy Organization, in conjunction
with the World Health Organization, has recently pub-
lished Guidelines for the Prevention of Allergy and Aller-
gic Asthma that include primary, secondary, and tertiary
prevention strategies [62,63]. The guidelines recommend
treating upper airway disease, such as AR, to prevent the
development of asthma. Evidence to show any preventive
effect of this strategy, however, is mostly lacking. There are
indications that pollen immunotherapy reduces the
development of asthma in children with seasonal rhinoc-
onjunctivitis [64], but again effects on so-called allergic
march are not known. Tertiary prevention strategies in the
World Allergy Organization/World Health Organization
guidelines – to prevent exacerbations and disease progres-
sion – emphasize the need to treat the underlying inflam-
matory process.
Conclusion
As inflammation and its relationship to remodeling in AR
and asthma are becoming better understood, the impor-
tance of anti-inflammatory treatment is increasingly
accepted. For patients with symptoms of asthma, it is
Cysteinyl leukotriene type 1 receptor mRNA and protein-positive cells in bronchial biopsies Figure 7
Cysteinyl leukotriene type 1 receptor mRNA and protein-positive cells in bronchial biopsies. Graphs of counts 
for cysteinyl leukotriene type 1 (cysLT1) receptor mRNA and protein-positive cells in bronchial biopsies of nonsmoker control 
(normal), stable asthma, and exacerbated asthma (exac) groups. Data expressed as the number of positive cells per mm2 of 
subepithelium. Dots show individual counts and horizontal bars show median values (Mann-Whitney U test). Reprinted with 
permission from Zhu and colleagues [35].
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Bronchial biopsies in asthma and chronic obstructive pulmonary disease Figure 8
Bronchial biopsies in asthma and chronic obstructive pulmonary disease. (a) Bronchial biopsy in a nonsmoker with 
mild asthma. Note thickening of the epithelial reticular basement membrane in comparison with (b). (b) Bronchial biopsy in a 
smoker with chronic obstructive pulmonary disease (alkaline phosphatase antialkaline phosphatase, original ×240). Reprinted 
with permission from Jeffery [66].
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important to detect inflammation (and remodeling) early
and to control inflammation in all its stages and severities.
Initial therapies comprise anti-inflammatory medication,
usually ICS or LTRA in mild asthma or ICS in more severe
asthma. This is usually supplemented with rapidly acting
β2-agonist as needed. In moderate to severe asthma, regu-
lar long-acting β2-agonists are used if anti-inflammatory
therapy fails to control the disease, as indicated by increas-
ing daily requirement for short-acting β2-agonist. The
combination of ICS and oral LTRA anti-inflammatory
therapy is one alternative approach to treatment and pro-
vides the option of treating airway inflammation as a
whole. Given the similarity that exists between the pat-
terns of inflammation seen in AR and asthma, patients
may best benefit from an approach that considers treating
the entire airway rather than only a part, as well as the skin
as necessary.
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